Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer

The determination of the alternative splicing isoforms expressed in cancer is fundamental for the development of tumor-specific molecular targets for prognosis and therapy, but it is hindered by the heterogeneity of tumors and the variability across patients. We developed a new computational method, robust to biological and technical variability, which identifies significant transcript isoform changes across multiple samples. We applied this method to more than 4000 samples from the The Cancer Genome Atlas project to obtain novel splicing signatures that are predictive for nine different cancer types, and find a specific signature for basal-like breast tumors involving the tumor-driver CTNND1. Additionally, our method identifies 244 isoform switches, for which the change occurs in the most abundant transcript. Some of these switches occur in known tumor drivers, including PPARG, CCND3, RALGDS, MITF, PRDM1, ABI1 and MYH11, for which the switch implies a change in the protein product. Moreover, some of the switches cannot be described with simple splicing events. Surprisingly, isoform switches are independent of somatic mutations, except for the tumor-suppressor FBLN2 and the oncogene MYH11. Our method reveals novel signatures of cancer in terms of transcript isoforms specifically expressed in tumors, providing novel potential molecular targets for prognosis and therapy. Data and software are available at: http://dx.doi.org/10.6084/m9.figshare.1061917 and https://bitbucket.org/regulatorygenomicsupf/iso-ktsp.

[1]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[2]  Jiang Cao,et al.  Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening , 2005, Journal of Cancer Research and Clinical Oncology.

[3]  Qian Zhu,et al.  Ontology-aware classification of tissue and cell-type signals in gene expression profiles across platforms and technologies , 2013, Bioinform..

[4]  D. Massi,et al.  S100A13 is a new angiogenic marker in human melanoma , 2010, Modern Pathology.

[5]  Daniel Q. Naiman,et al.  Simple decision rules for classifying human cancers from gene expression profiles , 2005, Bioinform..

[6]  S. Fuqua,et al.  RNA sequencing of cancer reveals novel splicing alterations , 2013, Scientific Reports.

[7]  Jenny G. Parvani,et al.  An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance , 2009, Molecular Cancer Therapeutics.

[8]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[9]  Anne-Mette K. Hein,et al.  Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis*S , 2008, Molecular & Cellular Proteomics.

[10]  F. Rousset,et al.  RBFOX2 Is an Important Regulator of Mesenchymal Tissue-Specific Splicing in both Normal and Cancer Tissues , 2012, Molecular and Cellular Biology.

[11]  Robert Castelo,et al.  Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. , 2005, Molecular cell.

[12]  B. Kreike,et al.  Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling. , 2011, Cancer research.

[13]  M. Ladomery,et al.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.

[14]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[15]  Colin N. Dewey,et al.  RNA-Seq gene expression estimation with read mapping uncertainty , 2009, Bioinform..

[16]  Kairong Cui,et al.  Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition , 2013, Cell Research.

[17]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[18]  J. Denecke,et al.  Diagnosis of N-acetylglutamate synthase deficiency by use of cultured fibroblasts and avoidance of nonsense-mediated mRNA decay , 2003, Journal of Inherited Metabolic Disease.

[19]  J. Venables,et al.  Multiple alternative splicing markers for ovarian cancer. , 2008, Cancer research.

[20]  Korbinian Strimmer,et al.  Entropy Inference and the James-Stein Estimator, with Application to Nonlinear Gene Association Networks , 2008, J. Mach. Learn. Res..

[21]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[22]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[23]  Timothy Sterne-Weiler,et al.  Exon identity crisis: disease-causing mutations that disrupt the splicing code , 2014, Genome Biology.

[24]  Carlos Caldas,et al.  Alpha‐6 integrin is necessary for the tumourigenicity of a stem cell‐like subpopulation within the MCF7 breast cancer cell line , 2008, International journal of cancer.

[25]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[26]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[27]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[28]  J. Pringle,et al.  Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms , 2009, Breast Cancer Research.

[29]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[31]  B. Blencowe,et al.  Regulation of Alternative Splicing by Histone Modifications , 2010, Science.

[32]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[33]  David Euhus,et al.  Identification of 5 novel genes methylated in breast and other epithelial cancers , 2010, Molecular Cancer.

[34]  Krishna R. Kalari,et al.  Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations , 2012, Front. Oncol..

[35]  T. Cooper,et al.  The pathobiology of splicing , 2010, The Journal of pathology.

[36]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[37]  L. Hood,et al.  Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas , 2007, Proceedings of the National Academy of Sciences.

[38]  Adrian R. Krainer,et al.  Alternative Splicing of SLC39A14 in Colorectal Cancer is Regulated by the Wnt Pathway* , 2010, Molecular & Cellular Proteomics.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[40]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[41]  Yi Xing,et al.  An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transition , 2010, The EMBO journal.

[42]  Christopher R. Cabanski,et al.  Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types , 2010, Clinical Cancer Research.

[43]  Lei Du,et al.  CD44 is of Functional Importance for Colorectal Cancer Stem Cells , 2008, Clinical Cancer Research.

[44]  Lior Pachter,et al.  Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer , 2010, Molecular Cancer Research.

[45]  J. Cheville,et al.  A p120 Catenin Isoform Switch Affects Rho Activity, Induces Tumor Cell Invasion, and Predicts Metastatic Disease* , 2008, Journal of Biological Chemistry.

[46]  Diane D. Liu,et al.  Fibulin-2 Is a Driver of Malignant Progression in Lung Adenocarcinoma , 2013, PloS one.

[47]  Ricky W. Johnstone,et al.  Epigenetics in cancer: Targeting chromatin modifications , 2009, Molecular Cancer Therapeutics.

[48]  L. Tranchevent,et al.  Endothelial, epithelial, and fibroblast cells exhibit specific splicing programs independently of their tissue of origin , 2014, Genome research.

[49]  J. Valcárcel,et al.  Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.

[50]  Yingtao Bi,et al.  Isoform level expression profiles provide better cancer signatures than gene level expression profiles , 2013, Genome Medicine.

[51]  Daniel Q. Naiman,et al.  Classifying Gene Expression Profiles from Pairwise mRNA Comparisons , 2004, Statistical applications in genetics and molecular biology.

[52]  Sam W. Lee,et al.  Hzf Determines Cell Survival upon Genotoxic Stress by Modulating p53 Transactivation , 2007, Cell.

[53]  Robert Gentleman,et al.  Using GOstats to test gene lists for GO term association , 2007, Bioinform..

[54]  B. Blencowe,et al.  Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer , 2010, Molecular and Cellular Biology.

[55]  M. Meyerson,et al.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.

[56]  T. Sasaki,et al.  Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma , 2012, Oncogene.

[57]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[58]  David Gentien,et al.  SF3B1 mutations are associated with alternative splicing in uveal melanoma. , 2013, Cancer discovery.

[59]  Luke Macyszyn,et al.  Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes , 2014, Nucleic acids research.

[60]  C. Ghigna,et al.  Oncogenic Alternative Splicing Switches: Role in Cancer Progression and Prospects for Therapy , 2013, International journal of cell biology.

[61]  T. Hudson.  Genome variation and personalized cancer medicine , 2013, Journal of internal medicine.